Cancer Genetics, NovellusDx Sign Merger Agreement

Sep 18, 2018

|

NEW YORK (GenomeWeb) — Cancer Genetics (CGI) and NovellusDx announced today that they have agreed to merge.

The transaction will combine CGI's portfolio of cancer tests and laboratory service offerings with NovellusDx's next-generation sequencing and machine-learning technologies for cancer treatment response prediction.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Cancer Genetics, NovellusDx Sign Merger Agreement

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

United Airlines Launches COVID-19 Testing Program for Travelers to Hawaii

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

Sponsorships